New Nukes, Old Nukes
Nuclear Waste
How to get overwhelmed by the data on new nukes, old nukes & lots of
different classes of ART at AIDS 2014
by Mariel...
Barriers to Treatment Use
LifeGuide
Opening Doors
A new survey uncovers barriers to treatment
by Chael Needle
There’s an old chestnut that goes something like this: People won’t make a change...
HIV Therapeutic Vaccine Advances
Treatment Horizons
Another Kind of Morning
HIV therapeutic vaccines try to come of age
by Mariel Selbovitz, MPJ, and David Miller
Despite over three decades of research on...
Editing Genes for a Cure
Close to the Edit
A functional cure candidate modifies genes to create HIV-resistant cells
by Chael Needle
Gary Blick, MD, AAHIVS, Medical & Research Director of CIRCLE...
Mighty Mouse
Mighty Mouse
A humanized BLT mouse model creates a vital platform for drug discovery
by Chael Needle
In the early stages of drug discovery, many candidates that...
Host Restrictive Factors
The Deeper End of the Ocean
Host restrictive factors create research excitement
by Mariel Selbovitz, MPH, and David Miller
The doors on viral host restrictive factors (HRFs),...
HPV Immunotherapy Research
Warts & All
An immunotherapy candidate seeks to address complications from HPV
by Chael Needle
Human papillomavirus (HPV) is the most common sexually transmitted infection, but, according...
Introducing Dolutegravir
Treatment Horizons by Chael Needle
Surpassing Expectations
ViiV Healthcare introduces its first FDA-approved agent
ViiV Healthcare is exclusively devoted to the treatment of HIV disease, and the...
AGS-004 Immunotherapy
Treatment Horizons by Chael Needle
Fully Personalized
An immunotherapy candidate stimulates T-cell responses via patient-specific antigens
Previous studies have established immunotherapy candidate AGS-004, both as a single...
Safety Net
Treatment Horizons by Chael Needle
A nonprofit creates a new support system for the uninsured
Joining Merck and ViiV Healthcare, Gilead Sciences is now supporting and...